222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details
臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05441826 (ClinicalTrials.gov) | May 3, 2022 | 7/6/2022 | Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) | A Phase 2 Study of VB119 in Adult Subjects With Steroid-Sensitive Primary Minimal Change Disease (MCD) or Primary Focal Segmental Glomerulosclerosis (FSGS) | Minimal Change Disease;Focal Segmental Glomerulosclerosis | Drug: VB119 | ValenzaBio, Inc. | NULL | Active, not recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |
| 2 | NCT04652570 (ClinicalTrials.gov) | May 5, 2021 | 23/11/2020 | Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy | A Phase 1b/2a Study of VB119 in Adult Subjects With Primary Membranous Nephropathy | Membranous Nephropathy | Drug: VB119 | ValenzaBio, Inc. | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 1/Phase 2 | United States;Mexico;United Kingdom |